A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Ribociclib (Primary) ; Everolimus; Exemestane
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 04 Oct 2019 Planned End Date changed from 16 Sep 2019 to 11 Sep 2020.
- 29 Dec 2018 This trial has been completed in Spain.
- 19 Nov 2018 Planned End Date changed from 28 Sep 2018 to 16 Sep 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History